AJU-A51 + A51R3

AJU-A51 + A51R3 is a fixed-dose combination therapy for type 2 diabetes mellitus, consisting of **dapagliflozin** and **linagliptin** (AJU-A51) plus **A51R3** (likely a related investigational or reference drug used in combination studies). Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, lowering blood glucose by increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that increases incretin levels, enhancing insulin release and lowering glucagon secretion. This combination is developed for patients with inadequate glycemic control on metformin and DPP-4 inhibitors, demonstrating significant HbA1c reduction and good tolerability in phase 3 trials[1][2][3][4][5][7].

Other names

AJU-A51AJU-A-51AJU-A 51A51R3A-51R3A 51R3